Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Innovation Pharmaceuticals IPIX
(Total Views: 395)
Posted On: 03/08/2017 12:50:20 PM
Post# of 72447
Avatar
Posted By: incubus
Cellceutix reports encouraging early data from mid-stage study of Brilacidin in UC; shares ahead 4%

Mar. 8, 2017 11:36 AM ET|About: Cellceutix Corp. (CTIX)|By: Douglas W. House, SA News Editor

Thinly traded nano cap Cellceutix (OTCQB:CTIX +3.8%) perks up on the heels of its announcement of positive interim results from a Phase 2 clinical trial assessing antibiotic Brilacidin to induce remission in patients with mild-to-moderate ulcerative colitis (UC).

All 12 subjects in the first two cohorts achieved a beneficial response, while 50% achieved clinical remission at day 42. The remaining six patients achieved a partial response.

Brilacidin is a member of a new class of antibiotics calledĀ defensin-mimetics, which are modeled after host defense proteins. These are the "front line" of defense in the human immune system. An oral rinse formulation is in Phase 2 development for the treatment of chemoradiation-associated oral mucositis.

http://seekingalpha.com/news/3249599-cellceut...email_link













(0)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site